Enemark M, Hemmingsen J, Jensen M, Kridel R, Ludvigsen M
Int J Mol Sci. 2024; 25(20).
PMID: 39456961
PMC: 11508793.
DOI: 10.3390/ijms252011179.
Enemark M, Jensen M, Andersen M, Plesner T, Hamilton-Dutoit S, Ludvigsen M
Cancers (Basel). 2024; 16(20).
PMID: 39456647
PMC: 11506075.
DOI: 10.3390/cancers16203553.
Bai B, Wise J, Vodak D, Nakken S, Sharma A, Blaker Y
Blood Cancer J. 2024; 14(1):147.
PMID: 39191762
PMC: 11350178.
DOI: 10.1038/s41408-024-01124-5.
Tsuyuki Y, Karube K
J Clin Exp Hematop. 2024; 64(2):144-148.
PMID: 38811196
PMC: 11303967.
DOI: 10.3960/jslrt.23060.
Timm T, Hild C, Liebisch G, Rickert M, Lochnit G, Steinmeyer J
Cells. 2023; 12(13).
PMID: 37443777
PMC: 10340184.
DOI: 10.3390/cells12131743.
Advances in the multi-omics landscape of follicular lymphoma.
Xu T, Zheng Z, Zhao W
Int J Biol Sci. 2023; 19(6):1955-1967.
PMID: 37063433
PMC: 10092758.
DOI: 10.7150/ijbs.80401.
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
Han G, Deng Q, Marques-Piubelli M, Dai E, Dang M, Ma M
Blood Cancer Discov. 2022; 3(5):428-443.
PMID: 35687817
PMC: 9894575.
DOI: 10.1158/2643-3230.BCD-21-0075.
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.
Bennett J, Starczynowski D
Curr Opin Hematol. 2021; 29(1):8-19.
PMID: 34743084
PMC: 8654269.
DOI: 10.1097/MOH.0000000000000693.
Overexpression of microRNA-340-5p Ameliorates Inflammatory Response and Intracellular Survival of in Alveolar Type II Cells.
Zhang B, Li H, Zhang J, Hang Y, Xu Y
Infect Drug Resist. 2021; 14:1573-1584.
PMID: 33911883
PMC: 8071707.
DOI: 10.2147/IDR.S291867.
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.
Oksvold M, Berglund U, Gad H, Bai B, Stokke T, Rein I
Sci Rep. 2021; 11(1):6317.
PMID: 33737576
PMC: 7973795.
DOI: 10.1038/s41598-021-85613-8.
Fusion Transcripts of Adjacent Genes: New Insights into the World of Human Complex Transcripts in Cancer.
Barresi V, Cosentini I, Scuderi C, Napoli S, Di Bella V, Spampinato G
Int J Mol Sci. 2019; 20(21).
PMID: 31652751
PMC: 6862657.
DOI: 10.3390/ijms20215252.
DUBbing Down Translation: The Functional Interaction of Deubiquitinases with the Translational Machinery.
Kapadia B, Gartenhaus R
Mol Cancer Ther. 2019; 18(9):1475-1483.
PMID: 31481479
PMC: 6727985.
DOI: 10.1158/1535-7163.MCT-19-0307.
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M
Front Immunol. 2019; 10:1943.
PMID: 31475004
PMC: 6702952.
DOI: 10.3389/fimmu.2019.01943.
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
Steen C, Leich E, Myklebust J, Lockmer S, Wise J, Wahlin B
Haematologica. 2019; 104(10):e460-e464.
PMID: 30846496
PMC: 6886427.
DOI: 10.3324/haematol.2018.209080.
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.
Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M
Oncoimmunology. 2019; 8(3):1554175.
PMID: 30723586
PMC: 6350687.
DOI: 10.1080/2162402X.2018.1554175.
TRIMming down to TRIM37: Relevance to Inflammation, Cardiovascular Disorders, and Cancer in MULIBREY Nanism.
Brigant B, Metzinger-Le Meuth V, Rochette J, Metzinger L
Int J Mol Sci. 2018; 20(1).
PMID: 30586926
PMC: 6337287.
DOI: 10.3390/ijms20010067.
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.
Singer J, Fleischman A, Al-Fayoumi S, Mascarenhas J, Yu Q, Agarwal A
Oncotarget. 2018; 9(70):33416-33439.
PMID: 30279971
PMC: 6161786.
DOI: 10.18632/oncotarget.26058.
Comprehensive analysis of differentially expressed profiles of lncRNAs and mRNAs reveals ceRNA networks in the transformation of diffuse large B-cell lymphoma.
Tian L, He Y, Zhang H, Wu Z, Li D, Zheng C
Oncol Lett. 2018; 16(1):882-890.
PMID: 29963159
PMC: 6019896.
DOI: 10.3892/ol.2018.8722.
From genetics to the clinic: a translational perspective on follicular lymphoma.
Huet S, Sujobert P, Salles G
Nat Rev Cancer. 2018; 18(4):224-239.
PMID: 29422597
DOI: 10.1038/nrc.2017.127.
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson S, Huse K, Kolstad A, Beiske K, Pende D, Steen C
Clin Cancer Res. 2017; 24(4):870-881.
PMID: 29217528
PMC: 5815910.
DOI: 10.1158/1078-0432.CCR-17-2337.